Shared Decision Making in Managing Idiopathic and Neurogenic OAB

To start this activity, click Begin at the bottom of this pageFSGS: Talking Points for the Practicing Nephrologist

Release Date: September 15, 2014

Expiration Date: September 15, 2015

Estimated time to complete the educational activity: 1 hour

This activity is provided by Global Education Group, Haymarket Medical Education (HME) is the education partner, and it is supported by an educational grant from Allergan, Inc., and Astellas Scientific and Medical Affairs, Inc.

Statement of Need: Data suggest that physicians often fail to communicate adequately with patients to select individualized therapy. Along with the prevalence of overactive bladder (OAB) and the frequent failure of initial therapy, this points to the need for urology specialists to heighten their diagnostic acuity for OAB and its comorbidities, and to strengthen their ability to communicate with patients to individualize treatment, improving efficacy, safety, and adherence.

Target Audience: This activity has been designed to meet the educational needs of urologists, urogynecologists, and other health care providers who treat patients with bladder dysfunction.

Educational Objectives: After completing the activity, the participant should be better able to:

Assess idiopathic overactive bladder (OAB), particularly in patients with comorbid diseases, recognizing the impact on quality of life
Assess treatment options for OAB based on the patient's needs, considering efficacy, safety, and improved adherence
Implement diagnostic strategies to identify patients with neurogenic detrusor overactivity (NDO) to more efficiently individualize treatment
Select, assess, and modify treatment for NDO to provide optimal individualized therapy
Discuss how to improve patient communication regarding current and emerging therapies and the impact of adherence


Accreditation Statement:
Global Education Group is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation Statement: Global Education Group designates this enduring educational activity for a maximum of 1.0 AMA PRA Category 1 Credit TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflicts of Interest: Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouse/ life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this activity:

Name of Faculty Reported Financial Relationship
Michael B. Chancellor, MD
Consultant/Independent Contractor: Allergan, Targacept, Inc., Lipella Pharmaceuticals, Inc., Cook Group Incorporated.
Grant/Research Support: Cook Group Incorporated, Medtronic, Inc.
Honoraria: Allergan
David A. Ginsberg, MD
Consultant/Independent Contract: Allergan
Honoraria: Allergan, Medtronic, Inc.
Victor W. Nitti, MD
Consultant/Independent Contractor: Allergan, Astellas, AMS, Coloplast, Ono Pharmaceutical Co., Ltd., Pneumoflex Systems, LLC, Serenity Pharmaceuticals, LLC, Theracoat
Speakers Bureau: Allergan
Stock Shareholder: Serenity Pharmaceuticals, LLC.


The planners and managers, Ashley Marostica, RN, MSN, Amanda Glazar, PhD, and Andrea Funk, of Global Education Group, have disclosed that they have no relevant financial relationships or conflicts of interest.

The content managers, Debra A. Hughes, MS, Mary Jo Krey, Lori Marrese, and Jody A. Charnow, of Haymarket Medical Education, have disclosed that they have no relevant financial relationships or conflicts of interest.

Disclosure of Unlabeled Use: This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and Haymarket Medical Education do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer: Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

Method of Participation: There are no fees for participating in and receiving CME credit for this activity. During the period September 15, 2014 through September 15, 2015, participants must: 1) read the learning objectives and faculty disclosures, 2) study the educational activity, 3) complete the posttest and submit it online. Physicians may register at www.myCME.com/renalandurologynews, and 4) complete the evaluation form online.

A statement of credit will be issued only upon receipt of a completed activity evaluation form and a completed post-test with a score of 70% or better.

Page 1 of 7
Loading links....
You must be a registered member of Renal and Urology News to post a comment.